Get the Stockscreener App
193.84
0.43%
-0.83
After Hours:
193.84
Biogen Inc stock is traded at $193.84, with a volume of 972.41K.
It is down -0.43% in the last 24 hours and down -5.33% over the past month.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
See More
Previous Close:
$194.67
Open:
$193.36
24h Volume:
972.41K
Relative Volume:
0.99
Market Cap:
$28.18B
Revenue:
$9.67B
Net Income/Loss:
$1.16B
P/E Ratio:
10.55
EPS:
18.37
Net Cash Flow:
$1.47B
1W Performance:
-1.01%
1M Performance:
-5.33%
6M Performance:
-10.11%
1Y Performance:
-24.58%
1-Day Range:
$192.28
$194.48
1-Week Range:
$188.78
$199.99
52-Week Range:
$188.78
$269.43
Biogen Inc Stock (BIIB) Company Profile
Name
Biogen Inc
Sector
Industry
Phone
(781) 464-2000
Address
225 BINNEY STREET, CAMBRIDGE, MA
Biogen Inc Stock (BIIB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-14-24 | Reiterated | Needham | Buy |
| Feb-14-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-24-24 | Downgrade | UBS | Buy → Neutral |
| Dec-20-23 | Resumed | Cantor Fitzgerald | Overweight |
| Dec-07-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Jul-27-23 | Initiated | Scotiabank | Sector Outperform |
| Jul-24-23 | Reiterated | UBS | Buy |
| May-01-23 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-17-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-26-22 | Upgrade | Goldman | Neutral → Buy |
| Oct-13-22 | Upgrade | Stifel | Hold → Buy |
| Oct-07-22 | Upgrade | Argus | Hold → Buy |
| Sep-28-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Sep-28-22 | Upgrade | Mizuho | Neutral → Buy |
| Sep-28-22 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Apr-18-22 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-08-22 | Downgrade | Stifel | Buy → Hold |
| Mar-03-22 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Feb-04-22 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Feb-04-22 | Reiterated | Barclays | Equal Weight |
| Feb-04-22 | Reiterated | BofA Securities | Neutral |
| Feb-04-22 | Reiterated | Cowen | Outperform |
| Feb-04-22 | Reiterated | Morgan Stanley | Overweight |
| Feb-04-22 | Reiterated | Needham | Buy |
| Feb-04-22 | Reiterated | Oppenheimer | Outperform |
| Feb-04-22 | Reiterated | RBC Capital Mkts | Sector Perform |
| Feb-04-22 | Reiterated | Robert W. Baird | Neutral |
| Feb-04-22 | Reiterated | Wedbush | Neutral |
| Feb-04-22 | Reiterated | Wells Fargo | Equal Weight |
| Feb-04-22 | Reiterated | Wolfe Research | Peer Perform |
| Jan-13-22 | Downgrade | Guggenheim | Buy → Neutral |
| Jan-12-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-10-21 | Resumed | Raymond James | Mkt Perform |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Neutral |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Sep-23-21 | Initiated | Needham | Buy |
| Jun-18-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jun-14-21 | Reiterated | Truist | Buy |
| Jun-11-21 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Jun-10-21 | Upgrade | UBS | Neutral → Buy |
| Jun-08-21 | Upgrade | Atlantic Equities | Underweight → Neutral |
| Jun-08-21 | Reiterated | Barclays | Equal Weight |
| Jun-08-21 | Upgrade | Citigroup | Sell → Neutral |
| Jun-08-21 | Reiterated | H.C. Wainwright | Buy |
| Jun-08-21 | Reiterated | Jefferies | Buy |
| Jun-08-21 | Reiterated | Morgan Stanley | Overweight |
| Jun-08-21 | Reiterated | RBC Capital Mkts | Sector Perform |
| Jun-08-21 | Upgrade | Robert W. Baird | Underperform → Neutral |
| Jun-08-21 | Reiterated | Stifel | Buy |
| Jun-08-21 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jun-07-21 | Upgrade | BofA Securities | Underperform → Neutral |
| Jun-07-21 | Upgrade | Cowen | Market Perform → Outperform |
| Jun-07-21 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Feb-05-21 | Downgrade | DZ Bank | Buy → Hold |
| Jan-29-21 | Upgrade | Stifel | Hold → Buy |
| Nov-10-20 | Upgrade | DZ Bank | Hold → Buy |
| Nov-09-20 | Downgrade | Atlantic Equities | Neutral → Underweight |
| Nov-09-20 | Downgrade | BofA Securities | Neutral → Underperform |
| Nov-09-20 | Downgrade | Cowen | Outperform → Market Perform |
| Nov-09-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-04-20 | Upgrade | BofA Securities | Underperform → Neutral |
| Nov-04-20 | Upgrade | Jefferies | Hold → Buy |
| Nov-04-20 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Oct-28-20 | Initiated | UBS | Neutral |
| Jul-27-20 | Upgrade | Morgan Stanley | Underweight → Overweight |
| Jun-22-20 | Downgrade | Barclays | Overweight → Equal Weight |
| Jun-22-20 | Reiterated | RBC Capital Mkts | Sector Perform |
| Jun-09-20 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Apr-23-20 | Downgrade | Citigroup | Neutral → Sell |
| Apr-23-20 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Jan-27-20 | Upgrade | Canaccord Genuity | Hold → Buy |
| Dec-13-19 | Upgrade | Credit Suisse | Underperform → Neutral |
| Dec-02-19 | Downgrade | Robert W. Baird | Neutral → Underperform |
View All
Biogen Inc Stock (BIIB) Latest News
Saratoga Research & Investment Management Cuts Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen Inc. (NASDAQ:BIIB) Short Interest Up 9.9% in September - MarketBeat
10,455 Shares in Biogen Inc. (NASDAQ:BIIB) Purchased by MBB Public Markets I LLC - MarketBeat
10,455 Shares in Biogen Inc. (NASDAQ:BIIB) Bought by MBB Public Markets I LLC - MarketBeat
1 Unstoppable Growth Stock Heading to $2 Trillion by 2030 - The Motley Fool
Neurologic Disorders Therapeutics Market Expecting Huge - openPR
SAGE, BIIB End Collaboration for Neurology Candidate SAGE-324 - Zacks Investment Research
Alzheimer's Disease (AD) Therapeutics Market Will Accelerate - openPR
SAGE Therapeutics’ SAGE-324 Collaboration with Biogen Ends - Yahoo Finance
Biogen ends Sage collab after negative trial results - The Pharma Letter
Toronto Dominion Bank Sells 12,436 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen to end Sage deal for neuro candidate - MSN
'Unfair Business Practices'?: Lawsuits Allege Big Pharma Multiple Sclerosis Drug Monopoly - Law.com
Biogen stock opened higher on positive lupus readout - MSN
Sage Therapeutics ends deal with Biogen for SAGE-324 products - Investing.com
Biogen Inc. stock outperforms competitors on strong trading day - MarketWatch
Biogen and Belgian partner UCB announce positive data from late-stage trial of lupus treatment - MSN
Biogen Terminates Collaboration With Sage Therapeutics For Neurological Disorder Candidate - AOL
Roche looks to grow Gazyva's reach with phase 3 lupus nephritis win - FiercePharma
Biogen walks away from Sage collab on essential tremor drug - The Business Journals
Biogen Terminates Collaboration With Sage Therapeutics For Neurological Disorder Candidate - Benzinga
Biogen Terminates Collaboration With Sage Therapeutics For Neurological Disorder Candidate - Yahoo Finance
Sage Therapeutics falls after Biogen terminates tremor drug partnership - XM
SAGE Therapeutics’ SAGE-324 Collaboration with Biogen Ends - TipRanks
Sage Therapeutics, Biogen End Licensing Agreement for Tremor Drug - MarketWatch
Sage Therapeutics announces discontinuation of SAGE-324 pact with Biogen - TipRanks
Sage regains SAGE-324 rights as Biogen exits partnershi - Investing.com
Sage Therapeutics Announces Discontinuation of the Collaboration with Biogen on the SAGE-324 Program - Business Wire
Roche, Biogen post late-stage win for kidney drug (OTCQX:RHHBY) - Seeking Alpha
Biogen's Lupus Candidate Meets Key Goals in Phase III Study - MSN
Biogen stock touches 52-week low at $189.44 amid challenges By Investing.com - Investing.com Australia
Biogen stock touches 52-week low at $189.44 amid challenges - Investing.com
City of Baltimore sues Biogen over allegedly paying PBMs to stave off Tecfidera generic competition - MM+M Online
BIIB: 3 Biotech Stocks Wall Street Predicts Will Skyrocket - StockNews.com
Biogen's Lupus Candidate Meets Key Goals in Phase III Study - Yahoo Finance
A scientific rebellion to get Europe to approve a controversial Alzheimer’s drug - EL PAÍS USA
Biogen's Lupus Candidate Meets Key Goals in Phase III Study - Zacks Investment Research
Biogen accused of ‘unlawful’ scheme to block MS drug competition, STAT reports - TipRanks
Pharmalittle: We're reading about Sanders and Novo CEO sparring, Roche refocusing, and more - STAT
Analysts Offer Predictions for Biogen Inc.'s FY2024 Earnings (NASDAQ:BIIB) - MarketBeat
Biogen lupus data brings ‘much-needed win,’ says Barclays - TipRanks
PEGylated Proteins Market: A Comprehensive Analysis of its - openPR
Biogen and UCB Promising Phase-III Trial Data for Lupus; CAR T-Cell Therapy Another Autoimmune Treatment Avenue - geneonline
Intech Investment Management LLC Reduces Holdings in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
UCB And Biogen Lifted By Promising Late-Stage Lupus Data - Scrip
Making an Impact with Analytics: Khalid’s Career Journey - Biogen
AMGN: 3 Biotech Stocks That Could Deliver Big Gains - StockNews.com
Baltimore claims Biogen ‘bribed’ PBMs to favor its pricey MS drug over generics - STAT
Biogen shares hold price target, buy rating on positive trial results - Investing.com
Biogen, UCB's lupus drug succeeds in late-stage trial - The Business Journals
Biogen (NASDAQ:BIIB) Rating Reiterated by Needham & Company LLC - MarketBeat
Biogen Inc Stock (BIIB) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.63%
0.03%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):